Patent · US Active

Vaccine adjuvant compositions

US10881729B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

Children's Medical Center Corporation · US

Inventors

Simon D. van Haren · Somerville, US
Ofer Levy · Afula, IL
David J. Dowling · Watertown, US

Key dates

Filing date	Apr 17, 2015
Grant date	Jan 5, 2021
Priority date	—
Expiry date	Apr 17, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/24234
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-γ-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.